Mohtashamian Abbas, Ebrahimzadeh Armin, Shamekhi Zahra, Sharifi Nasrin
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Basic Science Research Institute, Kashan University of Medical Sciences, Kashan, Iran.
Sepidan Bagherololoom Higher Education College, Shiraz University of Medical Sciences, Shiraz, Iran.
Avicenna J Phytomed. 2023 Jan-Feb;13(1):18-33. doi: 10.22038/AJP.2022.20060.
Based on the results of previous studies, the effects of on some of the non-alcoholic fatty liver disease's (NAFLD) biomarkers were positive; however, there were conflicting results regarding other variables. Therefore, the present systematic review of clinical trials was designed to clarify whether effectively prevents the progression of NAFLD.
A search of four databases (Scopus, PubMed, Medline, and Google scholar) was conducted to identify the clinical trials that assessed the effects of supplementation on NAFLD. The outcome variables of interest were biomarkers of hepatic steatosis, liver enzymes, insulin resistance, and inflammation.
Overall, four randomized clinical trials (RCTs) were included. In three studies, hepatic steatosis grade decreased significantly after supplementation. Serum levels of liver enzymes reduced significantly in three of four included trials. In the only study that examined the effect of on insulin resistance parameters, all variables related to this factor were significantly reduced. In two included studies that measured biomarkers of inflammation, the serum levels of tumor necrosis factor α (TNF-α), high-sensitive C-reactive protein (hs-CRP), and interleukin 6 (IL-6) decreased significantly after intaking supplements.
Although the efficacy of on liver enzymes and the grade of hepatic steatosis was reported in some of the included studies, more well-designed clinical trials are needed to determine the definitive effects of on NAFLD. The present study provides suggestions that help to design future studies in this field.
基于先前的研究结果，[具体物质]对某些非酒精性脂肪性肝病（NAFLD）生物标志物有积极影响；然而，关于其他变量的结果存在冲突。因此，本系统评价临床试验旨在阐明[具体物质]是否能有效预防NAFLD的进展。
检索四个数据库（Scopus、PubMed、Medline和谷歌学术），以确定评估[具体物质]补充剂对NAFLD影响的临床试验。感兴趣的结局变量是肝脂肪变性生物标志物、肝酶、胰岛素抵抗和炎症。
总体而言，纳入了四项随机临床试验（RCT）。在三项研究中，补充[具体物质]后肝脂肪变性分级显著降低。在四项纳入试验中的三项中，肝酶血清水平显著降低。在唯一一项研究[具体物质]对胰岛素抵抗参数影响的试验中，与该因素相关的所有变量均显著降低。在两项测量炎症生物标志物的纳入研究中，摄入[具体物质]补充剂后，肿瘤坏死因子α（TNF-α）、高敏C反应蛋白（hs-CRP）和白细胞介素6（IL-6）的血清水平显著降低。
尽管在一些纳入研究中报告了[具体物质]对肝酶和肝脂肪变性分级的疗效，但需要更多设计良好的临床试验来确定[具体物质]对NAFLD的确切影响。本研究提供了有助于设计该领域未来研究的建议。
